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Objective. To describe the echocardiographic ﬁndings in critically ill patients with AIDS and their impact on clinical outcome.
Design. A retrospective chart review of consecutive AIDS patients over 18 years of age, who had a trans-thoracic echocardiogram
performedduringthecourseofintensivecareunitstayoverthecourseof2yearsatatertiarycarehospital. Mainoutcomemeasures.
The prevalence of echocardiogram abnormalities in this population and its impact on ICU mortality, ICU length of stay, hospital
mortality, hospital length of stay and 60 day survival. Results. Among 107 patients who met the inclusion criteria, an admission
echocardiogram was performed in 62 (58%). The prevalence of cardiac abnormalities was 60%. The most common admission
diagnosis was respiratory failure n = 27 (43%). The most common ﬁnding on echocardiogram was left ventricular (LV) dysfunc-
tion n = 31 (50%) followed by pulmonary hypertension n = 25 (40%). None of these ﬁndings had a signiﬁcant impact on clinical
outcomes. There was trend toward reduced 60 day survival among patients with depressed LV function. Conclusions. Although
echocardiogram abnormalities were prevalent among this population none of these ﬁndings had a signiﬁcant impact on ICU
mortality or hospital mortality and ICU length of stay or hospital length of stay.
1.Introduction
The CDC estimates that 56,300 new HIV infections occurred
in the United States in 2006 [1]. In the era of highly active
antiretroviral therapy the mortality from HIV has been de-
creasing [2–6]. More patients are admitted to the intensive
care unit for non-AIDS-associated illnesses than in the past
[2, 5–8]. Advances in echocardiogram technology have pro-
vided the critical care physicians with a reliable and nonin-
vasive method of determining cardiac function and chamber
sizes and to detect the presence of valve diseases and peri-
cardial disease. Due to its ready availability and noninvasive
nature, echocardiography is commonly used in the critically
ill population. A number of echocardiogram ﬁndings have
been described in the noncritically ill HIV population with
themostcommononesbeingpericardialeﬀusion,myocardi-
tis, dilated cardiomyopathy, endocarditis, and pulmonary
hypertension, while a recent prospective observational study
showed that 18% of the HIV patients had systolic, 26% had
diastolic dysfunction, and up to 57% had evidence of pul-
monary hypertension based on TR jet velocity [9, 10]. Peri-
cardial eﬀusion has also been shown to predict increased
mortality among HIV infected patients [11, 12]. Blanc et al.
performed a prospective echocardiographic study in HIV-
patients admitted to the intensive care unit (ICU) preceding
the highly active antiretroviral therapy (HAART) era and
found a similar prevalence of cardiac abnormalities as pre-
viously published studies [13]. Hakim et al. presented an
abstract of echocardiographic ﬁndings in hospitalized HIV
patientswhichshowedthat50%ofthepatientshaveechocar-
diographic abnormalities [14]. The prevalence of pulmonary
hypertension in HIV-infected patients has changed little
from the 1990s (0.5%), when HAART therapy was not read-
ily available to the 2000s (0.46%), when HAART therapy is
easily available [15, 16] .Th ep r ev a l e n c eo fp u l m o n a ryh ype r -
tension in critically ill patients with AIDS is not known.
Acquired immunodeﬁciency syndrome (AIDS) repre-
sentsthemostadvancedpartofthespectrumofHIVinfected2 Pulmonary Medicine
population. The CDC estimates that in 2006 there were
436,693 persons living with AIDS in the United States. More
AIDS patients get admitted to the intensive care unit due to
the changing spectrum of management in this era due to
availability of HAART therapy. Afessa et al. showed that
in their center higher APACHE II scores and transfer from
another hospital were associated with poor outcome [4]
however like most other studies, this study included patients
with HIV infection with or without AIDS. To date no studies
have described echocardiographic ﬁndings in critically ill
patients with AIDS in the HAART era and their impact on
clinical outcomes.
2. Methods
After approval by the institutional review board, we perfor-
med a retrospective analysis of consecutive AIDS patients
admitted to the medical intensive care unit of an urban ter-
tiary care center from 2005–2008. Patients who did not have
an echocardiogram done during ICU admission were ex-
cluded from the analysis. We collected demographics data,
admission diagnoses and calculated the Acute Physiology
and Chronic Health Evaluation (APACHE 2) Score. We also
documented ICU mortality, hospital mortality, and 60-day
survival. The use of HAART therapy, compliance with
HAART therapy, CD4 count, and HIV viral loads were also
recorded. The echocardiographic ﬁndings were documented
after a review of the echocardiogram reports. We also doc-
umented the presence and severity of pericardial eﬀusion,
right atrial dilation, left atrial dilation and size in cm,
evidence of pulmonary hypertension as deﬁned by TR jet
velocity greater than 2.5 meters per second (m/sec), esti-
mated pulmonary artery systolic (PAS) pressure, TR jet ve-
locity in m/s, right ventricular (RV) dilation, RV dysfunc-
tion, left ventricular (LV) dilation, LV end systolic (ES) and
end diastolic (ED) size in cm, LV ejection fraction (EF), and
LV fractional shortening in percentage. LV ejection fraction
measurements from echocardiogram results were catego-
r i z e da sn o r m a l( ≥55%), mildly depressed (45%–54%),
moderately depressed (35%–44%), and severely depressed
(<35%). We performed a descriptive and comparative anal-
ysis of the data. Mean and range or standard deviation was
used to describe normally distributed continuous data. Med-
ian and interquartile range (IQR 25–75) was used to describe
nonnormally distributed data, and percentages were used to
describe categorical data. A logistic regression analysis was
performed to evaluate the impact of multiple echocardio-
gram parameters on ventilator days, ICU mortality, hospital
mortality, and length of stays both in the ICU and the hos-
pital. A P value less than .05 was considered statistically sig-
niﬁcant. A logistic regression analysis was performed to
analyzetherelationshipbetweenvariables.Statisticalanalysis
was performed using JMP (Statistical Discovery by SAS,
Cary, NC, USA).
3. Results
From2005to2008,therewere107AIDSpatientsadmittedto
the medical ICU at our institute. 62 (58%) of these patients
Table 1: Demographics, length of stay, and mortality.
Age, yrs. mean ± SD 47 ±9
Sex
Male, number (%) 44 (70)
Female, number (%) 18 (29)
Race
Black, number (%) 56 (90)
Caucasian, number (%) 6 (10)
HAART therapy
Yes 19 (31)
No 43 (70)
CD4 count, mean ± SD 95 ±141
HIV viral load, copies/mL. mean ±SD 326270 ±561689
APACHE II score, mean ±SD 23.4 ±9.3
APACHE II predicted mortality, mean ±SD 47 ±26
ICU LOS, median (IQR 25–75) 3 (2–7)
Hospital LOS, median (IQR 25–75) 10 (5–19)
Ventilator days, median (IQR 25–75) 3 (2–7)
ICU mortality, number (%) 21 (33)
Hospital mortality, number (%) 21 (33)
LOS: length of stay; HAART: highly active antiretroviral therapy.
Table 2: Admission diagnosis.
Diagnosis Number (%)
Respiratory failure 27 (43)
Altered mental status 9 (14)
Sepsis 9 (14)
Pneumonia 4 (7)
Seizure 4 (7)
GI bleed 2 (3)
Ascites 2 (3)
Spinal cord compression 1 (1.6)
Diarrhea 1 (1.6)
Pneumothorax 1 (1.6)
Syncope 1 (1.6)
Paraplegia 1 (1.6)
had at least one echocardiogram done upon their admission
to the ICU and were included in the analysis. Demographics
are described in Table 1. The majority of the patients were
male (70%) and black (90%). Only a small number of these
patients was on HAART therapy n = 19 (31%), and only
10 of 19 (53%) were compliant with therapy based on docu-
mentation upon admission to the ICU. The most common
diagnosis was respiratory failure n = 27 (43%) (Table 2).
Mechanical ventilation was instituted in 43 of 62 (68%)
patients with median ventilator days of 3 (IQR 2–7). The
report of the ﬁrst echocardiogram done during the ICU stay
was reviewed, and the predeﬁned data were collected. The
echocardiogram was considered abnormal in 38 patients
(60%), with the most common abnormality being left ven-
tricular dysfunction n = 31 (50%) followed by evidence of
pulmonary hypertension n = 25 (40%) and pericardialPulmonary Medicine 3
Table 3: Echocardiogram ﬁndings.
Pericardial eﬀusion, number (%)† 14 (22)
Moderate size 1 (7)
Small size 13 (93)
Pulmonary HTN, number (%)† 25 (40)
Estimated PA systolic pressure mm Hg, mean ± SD 45 ±12
TR jet velocity m/sec, mean ± SD 2.9 ±0.3
RA dilatation, number (%)† 16 (26)
Mild 14 (87)
Marked 2 (13)
Right ventricular enlargement, number (%)† 11 (18)
Mild 9 (82)
Moderate 2 (18)
Right ventricular dysfunction, number (%)† 2( 4 )
Mild 1 (50)
Severe 1 (50)
LA size in cm, mean ± SD 3.7 ±0.7
LA dilation, number (%)† 19 (31)
Mild 11 (58)
Moderate 6 (32)
Severe 2 (10)
LV size in cm, mean ± SD
End systolic 3.4 ±1.1
End diastolic 4.8 ±0.8
LV ejection fraction (LVEF) %, mean ± SD 51 ±19
LV fractional shortening %, mean ± SD 33 ±11
LV dysfunction, number (%)† 31 (50)
Mildly depressed LVEF 6 (19)
Moderately depressed LVEF 8 (26)
Severely depressed LVEF 8 (26)
Hyperkinetic 8 (25)
Diastolic dysfunction 1 (3)
PA: pulmonary artery, TR: tricuspid regurgitation, LA: left atrium, and LV:
left ventricle.
†Some patients had more than one echocardiographic ﬁnding.
eﬀusion n = 14 (22%). Although LV dysfunction was seen in
31 patients, only 22 of these patients had depressed function,
one had diastolic dysfunction and the rest had hyperkinetic
function(Table 3).Inpatientsinwhomtherewasevidenceof
pulmonary hypertension, only one patient had a right-heart
catheterization done for management; however, no speciﬁc
pulmonary hypertension treatment was instituted. Among
patients who had pericardial eﬀusions, none had evidence
of tamponade or required pericardial drainage. The majority
of the abnormalities noticed on echocardiograms were in
patients with an admission diagnosis of respiratory failure
(39%) followed by sepsis (18%). Among the 25 patients with
pulmonary hypertension per echocardiogram, 9 (36%) had
respiratoryfailure,3(12%)hadpneumonia,mechanicalven-
tilation was instituted in 16 (64%), and concomitant LV
dysfunction was noticed in 14 (56%) of these patients. Al-
though a number of echocardiogram abnormalities were
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Figure 1: Kaplan-Meier survival curve for patients with echocar-
diographic ﬁndings of depressed LV function and normal LV func-
tion.
prevalent in this population, on logistic regression analysis
none of these ﬁndings had a signiﬁcant impact on mortality,
ventilator days and length of stay in the ICU or hospital.
Although not signiﬁcant, there was a trend towards reduced
60-day survival in patients with depressed LV function com-
pared to those with normal LV function (Figure 1). No cor-
relation was found between the presence of echocardiogram
abnormalities and CD4 counts or viral loads.
4. Discussion
This is the ﬁrst study to look at the echocardiogram ﬁndings
and its impact on clinical outcomes in critically ill patients
with AIDS in the era of HAART. Advances in critical care
medicine over the last two decades have resulted in im-
proved outcomes of patients with HIV infection and AIDS.
Echocardiography these days is done on almost every pa-
tient admitted to the intensive care units. The information
obtained from the echocardiogram does guide treatment in
majority of these patients and HIV patients are not diﬀerent
[13]. The ﬁrst cardiac manifestation of AIDS was described
in1983byAutranetal.,whentheypublishedacaseofcardiac
Kaposi’sarcomainaHaitianwoman[17].Sincethen,anum-
ber of studies have estimated the prevalence of cardiac in-
volvement in AIDS patients to range from 28% to 73%
[9, 11–13]. Echocardiographic abnormalities among hospi-
talizedHIVpopulationarereportedtobearound50%intwo
diﬀerent studies [13, 14]. The prevalence of abnormal echo-
cardiogram in our AIDS population was slightly higher than
previously reported for HIV population admitted to the ICU
by Blanc et al. [13]. In the study by Blanc et al., pericardial
eﬀusion was the most common (29%) abnormality followed
by LV dysfunction (22%). In the same study vegetations were
noted in 3%, and sepsis was the leading cause of admis-
sion to the ICU (90%). In our study LV dysfunction (50%)
and pulmonary hypertension (40%) were the most com-
mon abnormalities. No vegetations were noted. The higher4 Pulmonary Medicine
prevalence of LV dysfunction in this group may reﬂect the
availability of HAART, longer life span of AIDS patients, and
acquiring the infection at a later age. However in our cohort,
only 30% of our patient population was actually on drugs,
and even a smaller number were actually compliant with
therapy, making it possible that the lack of adequate control
of HIV infection may be the cause of the critical illness
and higher prevalence of echocadiographic abnormalities.
Anotherfactortobeconsideredisthepresenceofsepsisatthe
time of admission in our population. Myocardial dysfunc-
tion has been well documented in sepsis the spectrum of
dysfunction ranges from hyperkinetic function to depressed
EF [18]. It is diﬃcult to ascertain whether these abnormali-
ties were related to the underlying critical illness or to HIV
infection itself. We were able to compare echocardiograms
done during critical illness to a prior echocardiogram in
23 (36.5%) of the cases and almost all of them had similar
abnormalities documented. Due to the design of the study,
we were unable to evaluate whether or not these abnormal
ﬁndings on echocardiogram resulted in any change in man-
agement strategy. Another noteworthy ﬁnding was the high
prevalenceofmoderatepulmonaryhypertensionbyechocar-
diogram (40%) in this population. The prevalence of pul-
monary hypertension in noncritically ill HIV population
ranges from 0.03% to 7% in diﬀerent eras of HIV treatment
and from various regions of the world [19–22]. Although
right heart catheterization remains to be gold standard for
diagnosis of pulmonary arterial hypertension, an echocar-
diogram has been routinely used in studies to screen for pul-
monary hypertension in otherwise healthy HIV patients. In
this critically ill population the presence of pneumonia, res-
piratory failure, mechanical ventilation along with high
number of concomitant LV dysfunction rather than true
pulmonary arterial hypertension, likely explain the high pre-
valence of pulmonary hypertension noticed on echocardio-
gram.
There are several limitations to this study. The retro-
spective nature limits the ability to derive any conclusion in
regards to whether the ﬁndings noticed on echocardiogram
lead to any management change during the course of ICU
stay and hence limiting our ability to determine the impact
of these ﬁndings on clinical outcome. There was also no way
to determine whether standardized echocardiography tech-
niques were uniformly employed to obtain images.
Basedonourreview,therewasnoprognosticsigniﬁcance
of any single echocardiogram abnormality in this AIDS pop-
ulation. Whether an echocardiogram performed in the ICU
in this critically ill AIDS population leads to ﬁndings that
can signiﬁcantly impact management decision remains to be
seen.
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